INTERVIEWS

Guest: Dr. James Stringham

Presenter:  Neal Howard

Guest Bio: Dr. Stringham earned his doctoral degree in experimental psychology from the University of New Hampshire in 2003. During postdoctoral appointments at the Schepens Eye Research Institute at Harvard Medical School and the Medical College of Georgia, he conducted research on ocular lutein, age‐related macular degeneration, the effects of intense light on visual performance, and plasticity of the visual system.  Dr. Stringham then took a position as a visiting assistant professor at the University of Georgia, where he continued and extended a research program involving lutein and many facets of visual performance. In 2007, he became a senior vision scientist in the Air Force Research Laboratory (AFRL).  Currently he is a research scientist at the University of Georgia.

Segment overview: Dr. James Stringham, discusses “blue light”  and a condition called Computer Vision Syndrome and how reducing the effects of blue light significantly improve visual performance and overall eye health.

Guest: Anthony Moloney

Presenter: Tabetha Moreto

Guest Bio: Anthony Moloney is the CEO and founder of Melcare, an early stage biomedical company commercialising therapeutic products into a global market for eye, wound, skin and ENT care. Anthony has been the commercial partner for clinical trials in the UK, Germany and Australia investigating wound care and dry eye disease. He innovated the marketing of medical honey products in a global market as both a drug and medical device and was founder and CEO of now US-based Medihoney, which was awarded the 2008 Optus Platinum Award for Outstanding Business Contribution to Brisbane and IBM Award for Business Innovation. Anthony has an undergraduate Degree in Applied Science and Post-Graduate Master’s Degree in Technology and Engineering Management.

Segment overview: In today’s Health Supplier Segment, we are joined by Melcare Biomedical CEO Anthony Moloney here to discuss the results of research undertaken by the Queensland University of Technology into the use of its Optimel™ Manuka honey product range for the treatment of Meibomian Gland Dysfunction (MGD) induced dry eye and related dry eye conditions. Melcare Biomedical is a Queensland-based TGA licensed Medical Device manufacturer that offer therapeutic products for skin, wound and eye care using standardised medical honeys for a global market. Most of their ingredients are plant derived and their honey is sourced from the leptospermum (tea tree) plant growing in forest locations.

Overview

• Rates of severe anxiety and depression among unemployed people have soared by more than 50 % percent in the last four years as the impact of “harsh” austerity policies take their toll, The Independent can reveal. The UK Council for Psychotherapy (UKCP) said the Government’s reforms of welfare payments were to blame for the rise, as benefit cuts and sanctions “are having a toxic impact on mental health”.
• It’s the aim of the UK government’s latest plan to discourage smoking, ultimately driving the proportion of adult smokers down to the notional “endgame” level of less than 5% percent. “Our vision is nothing less than to create a smoke free generation,” says Steve Brine, minister for public and primary care, in his foreword to the plan, Towards a Smokefree Generation.
• The HMRC has ruled carers sleeping overnight to provide safety and reassurance should be be paid the national minimum wage for all hours. According to minimum wage legislation, employers must take into account shifts where staff are allowed to sleep as long as they are “at work and under certain work-related responsibilities”. Until recently, many overnight carers were paid a flat rate allowance for the ‘sleep-in’, with additional wages paid for work carried out.

Guest: Dr. Jacob Teitelbaum

Presenter: Neal Howard  

Guest Bio: Dr. Jacob Teitelbaum, Director of the Practitioners Alliance Network, is one of the most frequently quoted integrative medical authorities in the country. He is the author of the bestselling From Fatigued to Fantastic!, Pain Free, 1,2,3!, the Beat Sugar Addiction Now! series, Real Cause Real Cure, The Fatigue and Fibromyalgia Solution, The Complete Guide to Beating Sugar Addiction, and the popular free smartphone app Cures A-Z.

Segment overview: Dr. Teitelbaum discusses a new British Medical Journal study that confirms that NSAIDs increase the risk of heart attacks and he offers safe alternatives backed by published research to treat chronic pain.

Guest: Kiran Krishnan

Presenter: Neal Howard  

Guest Bio: Kiran is a research microbiologist and has been involved in the dietary supplement and nutrition market for the past 16 years. He comes from a strict research background, having spent several years with hands-on R&D in the fields of molecular medicine and microbiology at the University of Iowa. Kiran earned his Bachelor of Science degree in Microbiology at the University of Iowa; his undergraduate education was followed up with postgraduate research in Molecular Biology and Virology.

Segment overview: Kiran Krishnan discusses Gut Fermentation Syndrome, a chronic condition that occurs from an overgrowth of Candida.  This causes the same inflammation in the body and stress on the liver as when you consume alcohol.

Guest: Dr. Matthew R. Kaufman  

Presenter:  Neal Howard

Guest Bio: Dr. Matthew R. Kaufman, M.D. is a Plastic & Reconstructive Surgeon board certified by both the American Board of Plastic Surgery & the American Academy of Otolaryngology – Head and Neck Surgery. He is also a Fellow of the American College of Surgeons and is a member of The Rhinoplasty Society. Dr. Kaufman is co-Director of the Center for Treatment of Paralysis and Reconstructive Nerve Surgery at Jersey Shore University Medical Center, and a Clinical Assistant Professor of Surgery at the David Geffen UCLA Medical Center in Los Angeles, California.

Segment overview: Dr. Matthew Kaufman, the only known expert in the world to perform surgery on phrenic nerve injuries, explains phrenic nerve injury, one of his cases, and the textbook that he and his colleagues from The Institute for Advanced Reconstruction have collaborated on, “Rehabilitative Surgery – A Comprehensive Text for an Emerging Field”

Guest:  Kouris Kalligas

Presenter: Neal Howard

Guest Bio: As CEO and co-founder, Kouris Kalligas leads the strategic and operational direction of Therachat. Kouris has a rich history of working on innovative products in health and wellness and helping companies grow and scale. Previously, Kouris co-founded Addapp and spent over six years at Sappi Fine Paper as a supply chain service manager and lead business development manager overseeing innovation projects. He received his B.A. in International Economics & Development from Democritus University of Thrace, completed the ERASMUS program in International Business at the University of Gavle and earned his M.A. in International Relations from the University of Warwick.

Segment overview: Kouris Kalligas, Co-Founder and CEO of both Therachat and Addapp Corp. discusses a smart journaling tool that allows psychologists, therapists and counselors greater insight into their client’s life between sessions.  

Guest: Dr. Andrew Blauvelt

Presenter: Neal Howard

Guest Bio: Andy Blauvelt hails from Portland, OR, and is President and Investigator at Oregon Medical Research Center, a small business dedicated to performing high quality clinical studies in dermatology. A native of Michigan, he received his undergraduate degree in Electrical Engineering at Purdue University, his medical degree at Michigan State University, and his MBA from Portland State University/Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami from 1989-1992 and in basic immunology and virology at the National Institutes of Health (NIH) from 1992-1996. He has held senior staff positions at the NIH, as Professor of Dermatology and Microbiology at OHSU, and as Chief of Dermatology at the Portland VA Medical Center. Andy’s clinical and research expertise is in immunology, virology, infectious diseases, psoriasis, atopic dermatitis, and biologic therapies for complex medical dermatology patients, having published over 200 papers and spoken across the world on these topics. Dr. Blauvelt was elected into the American Society for Clinical Investigation in 2004, a leading society for physician-scientists, and is an elected member of the International Psoriasis Council, the premier group of psoriasis experts in the world.

Segment overview: Andrew Blauvelt, MD, MBA, President of the Oregon Medical Research Center, discusses the recently FDA approved medication TREMFYA™ (GUSELKUMAB), the first and only biologic that selectively blocks IL-23, a cytokine that is thought to play a key role in plaque psoriasis, for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Presenter: Neal Howard

Guest Bio: Dr. David Spetzler joined Caris Life Sciences in August of 2009, and has held several management positions with increasing responsibilities during his tenure. He currently serves as President and Chief Scientific Officer and provides executive leadership for the company’s service lines, Caris Molecular Intelligence® and ADAPT Biotargeting System™.

Prior to his position at Caris, Dr. Spetzler was a member of the research faculty at Arizona State University where he developed multiplexed nanotechnologies for single molecule detection of nucleic acid and protein targets. At Arizona State University Dr. Spetzler earned an MS from the School of Mathematical and Statistical Science in Computational Bioscience, a Ph.D. in Molecular Cellular Biology and an MBA. Dr. Spetzler is an adjunct faculty member of the molecular cellular biology program at Arizona State University.

Segment overview: David Spetzler, Chief Scientific Officer at Caris Life Sciences to talks about their involvement with several studies where cancer is being treated based on molecular profile rather than its site of origin.